Please login to the form below

Not currently logged in
Email:
Password:

tremelimumab,

This page shows the latest tremelimumab, news and features for those working in and with pharma, biotech and healthcare.

Merck’s Keytruda scores in frontline lung cancer yet again

Merck’s Keytruda scores in frontline lung cancer yet again

AZ’s combination of Imfinzi (durvalumab) and tremelimumab missed the PFS endpoint in the MYSTIC trial last year but is continuing to an overall survival read-out.

Latest news

More from news
Approximately 5 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Pharma deals during July 2014 Pharma deals during July 2014

    tremelimumab. Existing partners Bristol-Myers Squibb (BMS) and Ono Pharmaceutical also announced that they will jointly develop and commercialise multiple immunotherapies as single and combination treatments.

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    2 trials for NSCLC, and tremelimumab, an anti-CTLA4 MAb in phase 2 for the rare cancer mesothelioma. “

  • Pharma deals during August 2013 Pharma deals during August 2013

    The $500m acquisition of Amplimmune marries well with Medimmune's existing commitment to cancer immunotherapy, which includes not only the anti-PD1 mAB MEDI-4736 but also tremelimumab (CLTA-4 mAB)

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Redline Strategic

We are a healthcare consultancy, specialising in people and experiences. Using innovative research methods to capture the thoughts of real...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics